CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Laser Treatment for Onychomycosis

Governs coverage stance for laser/device-based treatments for onychomycosis for Blue Cross Blue Shield - Rhode Island members; describes medical necessity determination and coding guidance applicable to providers seeking reimbursement.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyLaser Treatment for Onychomycosis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDo not request authorization for laser treatment because the therapy is considered not covered/not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredcoverage stance

No specific CPTcoding

Insufficientevidence

KOH/culture/histodiagnostics

Coverage Criteria

Not Medically Necessary / Not Covered

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyLaser Treatment for Onychomycosis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDo not request authorization for laser treatment because the therapy is considered not covered/not medically necessary.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Randomized controlled trials of laser therapy for onychomycosis have produced mixed results and suffer from methodological limitations. Some trials reported improvements in clinical outcomes while others did not, and clinical versus mycological outcomes sometimes differed. Limitations cited include inconsistent blinding of outcome assessment and other design issues, so the available RCT evidence does not permit determination of whether laser treatment improves meaningful health outcomes.

Provider Actions and Billing

Prior Authorization

Prior Authorization Required

Prior authorization is not required for laser treatment of onychomycosis because prior authorization is not applicable for this policy. However, claims for laser therapy may still be denied as the treatment is considered not covered / not medically necessary under this policy.

Prior authorization: Not applicable
Denial risk: Laser therapy considered not covered / not medically necessary

Documentation Required

Diagnostic Documentation Required

Document diagnostic confirmation of onychomycosis prior to treatment. Acceptable diagnostic methods include potassium hydroxide (KOH) preparation, fungal culture, or histologic examination. Include results and method used in the medical record to support diagnosis and medical decision-making.

Acceptable diagnostic methods: KOH preparation, fungal culture, histology
Document method and results in the medical record

Step Therapy

Step Therapy / Prior Treatment Documentation

Step therapy context: document prior use of topical and/or systemic antifungal treatments and a documented discussion of risks and benefits before considering device-based therapies. Record the specific agents used (eg, topical ciclopirox or amorolfine; oral terbinafine or itraconazole), treatment durations, response, and any adverse effects or contraindications that would justify alternative approaches.

Document prior topical antifungal therapy (agent, duration, response)
Document prior systemic antifungal therapy when used (agent, duration, response, adverse effects)
Document clinician-patient discussion of risks/benefits and rationale for proceeding to device-based therapy

Denial Risk

Denial Risk for Laser Therapy

Claims for laser treatment of onychomycosis may be denied as not covered / not medically necessary per policy statement. Even when diagnostic documentation and prior treatment information are provided, services may be adjudicated as non-covered based on insufficient evidence of clinical benefit.

Policy statement: Laser treatment is considered not covered / not medically necessary
Even with documentation, expect possible claim denial

Background

Onychomycosis is a common fungal nail infection treated most often in toenails and evaluated by clinical and mycological outcomes. Risk factors associated with onychomycosis include increasing age and comorbid conditions such as diabetes, obesity, peripheral vascular disease, and immunosuppression. Standard treatments include topical and systemic antifungals that require prolonged courses and have limited efficacy; oral agents carry risks such as hepatotoxicity. Laser systems aim to treat onychomycosis via selective photothermolysis to heat the nail bed and disrupt fungal growth, typically delivered in one or a few clinic sessions, but current evidence is inadequate to confirm benefit on health outcomes.

Definitions

Selective photothermolysis and mechanism

DefinitionSelective photothermolysis: precise targeting of tissue using a specific wavelength of light so absorbed energy generates heat in the target while sparing surrounding tissue

Mechanism — target and goalLaser energy is absorbed in the nail unit with the aim of heating the nail bed to temperatures sufficient to disrupt fungal growth (approximately 40–60°C)

Mechanism — tissue selectivityHeat generated by the absorbed light is intended to damage the fungal target while avoiding necrosis of surrounding tissues

Rationale for useProposed advantages include greater tissue penetration than topical agents and the possibility of one or a few clinic sessions rather than prolonged treatment courses

Diagnostic confirmation methods

Potassium hydroxide (KOH) preparationListed as a method to confirm diagnosis of onychomycosis

Fungal cultureListed as a method to confirm diagnosis of onychomycosis

HistologyListed as a method to confirm diagnosis of onychomycosis

17999	Unlisted procedure, skin, mucous membrane and subcutaneous tissue
96999	Unlisted special dermatological service or procedure

17999	Unlisted procedure, skin, mucous membrane and subcutaneous tissue
96999	Unlisted special dermatological service or procedure

OpenPayer

Laser Treatment for Onychomycosis

Coverage Criteria

Coding Guidance

Provider Actions and Billing

Background

Definitions